



PuriCore Wins Emerging Life Sciences Company of the Year Award

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, December 4, 2009 — [PuriCore](#) (LSE: PURI), the life sciences company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, was named as winner of the Emerging Life Sciences Company of the Year award, at the Eastern Technology Council's 17th annual Enterprise Awards gala. The Eastern Technology Council is the leading trade organization for life sciences and technology leadership, business development, and entrepreneurship in the Greater Philadelphia Region, serving more than 700 member companies.

Greg Bosch, Chief Executive Officer of PuriCore, said:

"We owe this honor to our innovative and incredibly dedicated teams in the US and UK. They have taken this simple and elegant science and developed it into far-reaching and market-leading clean technology products while also focusing on our customers, continued growth, and creating shareholder value."

Contact:

Jennifer Guinan	Greg Bosch, CEO
Sage Strategic Marketing	Darren Weiss, CFO
610.410.8111	PuriCore
Jennifer@sagestrat.com	484.321.2700

About PuriCore

[PuriCore](#) plc (LSE: PURI) is a life sciences company focused on developing and commercializing proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of *C.difficile*, *E.coli*, HIV, Human and Animal Influenza (including H1N1 and H5N1), *Legionella*, *MRSA*, *M.tuberculosis*, Norovirus, and *Salmonella*. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford and Clevedon, UK.

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.